Related references
Note: Only part of the references are listed.Molecular and clinical diversity in primary central nervous system lymphoma
I. Hernandez-Verdin et al.
ANNALS OF ONCOLOGY (2023)
Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways
Jennifer Edelmann et al.
ISCIENCE (2021)
A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia
T. Roderick Docking et al.
NATURE COMMUNICATIONS (2021)
Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis
Stefanie Schlager et al.
Oncotarget (2020)
TEOA Inhibits Proliferation and Induces DNA Damage of Diffuse Large B-Cell Lymphoma Cells Through Activation of the ROS-Dependent p38 MAPK Signaling Pathway
Xingxing Yu et al.
FRONTIERS IN PHARMACOLOGY (2020)
Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces
Sabina Sangaletti et al.
EBIOMEDICINE (2020)
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Targeting the Bcl-2 Family in B Cell Lymphoma
Clare M. Adams et al.
FRONTIERS IN ONCOLOGY (2019)
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806
Daniel O. Persky et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Past, Present, and Future of Rituximab-The world's First Oncology Monoclonal Antibody Therapy
Timothy M. Pierpont et al.
FRONTIERS IN ONCOLOGY (2018)
Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma
Fen Yang et al.
FRONTIERS IN PHARMACOLOGY (2018)
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials
A. Castellino et al.
BLOOD CANCER JOURNAL (2018)
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
Daniel J. Landsburg et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Umberto Vitolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
Gustaaf W. van Imhoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group
Frederic Peyrade et al.
LANCET HAEMATOLOGY (2017)
Rituximab: 13 open questions after 20 years of clinical use
Francesca Pavanello et al.
CANCER TREATMENT REVIEWS (2017)
Dissection of transcriptional and cis-regulatory control of differentiation in human pancreatic cancer
Giuseppe R. Diaferia et al.
EMBO JOURNAL (2016)
Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Bertrand Coiffier et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma
Michael Herold et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
PROPER: comprehensive power evaluation for differential expression using RNA-seq
Hao Wu et al.
BIOINFORMATICS (2015)
Targeting Microtubules by Natural Agents for Cancer Therapy
Eiman Mukhtar et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
Sarah K. Knutson et al.
PLOS ONE (2014)
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
Christian Klein et al.
MABS (2013)
Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis
Melanie S. Joy et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
Myron S. Czuczman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Pharmacokinetics of Prednisolone at Steady State in Young Patients With Systemic Lupus Erythematosus on Prednisone Therapy: An Open-Label, Single-Dose Study
Anna Carmela P. Sagcal-Gironella et al.
CLINICAL THERAPEUTICS (2011)
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2011)
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
Marie Cargnello et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2011)
Antibodies against CD20 or B-Cell Receptor Induce Similar Transcription Patterns in Human Lymphoma Cell Lines
Andreas Franke et al.
PLOS ONE (2011)
Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives
Giulia Motta et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2010)
Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass
Deise Raquel Barpe et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group
Boris Labar et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno et al.
NATURE (2009)
Acquired resistance to rituximeb is associated with chemotherapy resistance resulting from decreased Bax and Bak expression
Scott H. Olejniczak et al.
CLINICAL CANCER RESEARCH (2008)
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
Robert Marcus et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-Cell lymphoma with analysis of germinal center and post-germinal center biomarkers
Wyndham H. Wilson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers et al.
BLOOD (2006)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20m Ab) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention
AR Jazirehi et al.
ONCOGENE (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Rituximab inhibits p38 MAPK activity in 2F7 BNHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance
MI Vega et al.
ONCOGENE (2004)
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
R Forstpointner et al.
BLOOD (2004)
Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis
Y Liao et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects
AL Rose et al.
BLOOD (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
RE Davis et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Share Paper
